Skip to main content
Article thumbnail
Location of Repository

The Genomic and Proteomic Content of Cancer Cell-Derived Exosomes

By Meredith C. Henderson and David O. Azorsa


Exosomes are secreted membrane vesicles that have been proposed as an effective means to detect a variety of disease states, including cancer. The properties of exosomes, including stability in biological fluids, allow for their efficient isolation and make them an ideal vehicle for studies on early disease detection and evaluation. Much data has been collected over recent years regarding the messenger RNA, microRNA, and protein contents of exosomes. In addition, many studies have described the functional role that exosomes play in disease initiation and progression. Tumor cells have been shown to secrete exosomes, often in increased amounts compared to normal cells, and these exosomes can carry the genomic and proteomic signatures characteristic of the tumor cells from which they were derived. While these unique signatures make exosomes ideal for cancer detection, exosomes derived from cancer cells have also been shown to play a functional role in cancer progression. Here, we review the unique genomic and proteomic contents of exosomes originating from cancer cells as well as their functional effects to promote tumor progression

Topics: Oncology
Publisher: Frontiers Research Foundation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2012). 7Henderson and Azorsa Cancer cell-derived exosomes
  2. (2006). Alzheimer’s disease beta-amyloid peptides are released in association with exosomes.
  3. (2011). Amphiregulin exosomes increase cancer cell invasion.
  4. (2009). Anchorage-independent growth of breastcarcinomacellsismediatedby serum exosomes.
  5. and Lotvall,J.O.(2007).Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
  6. and Tewari,M.(2011).Argonaute2complexescarryapopulationofcirculatingmicroRNAsindependentof vesicles in human plasma.
  7. (2011). as a novel template for clinical diagnostics.
  8. (2000). cancer.Cell 100,
  9. (2009). CD44v6 dependence of premetastatic niche preparation by exosomes.
  10. (2010). Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosomeinduced endothelial cell activation.
  11. (2011). Characterizationof solubleandexosomal forms of the EGFR released from pancreatic cancer cells.
  12. (2006). Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
  13. (2009). Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer.
  14. (2009). Claudincontaining exosomes in the peripheralcirculationof womenwithovarian cancer.
  15. (2009). Colorectal cancer cellderived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells.
  16. (2003). Constitutive protein Frontiers in Oncology | Cancer Genetics
  17. (2006). Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesisandinflammation.J.Vasc.Res.43,
  18. D.(2007).Expressionprofilingidentifies microRNA signature in pancreatic cancer.
  19. (2004). Developmental endothelial locus-1 (Del1), a novel angiogenic protein: its role in ischemia.
  20. (2006). Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
  21. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery.
  22. (2009). ExoCarta: a compendium of exosomal proteins and RNA.
  23. (1991). Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release isamajorrouteforexternalizationof obsolete membrane proteins.
  24. (2011). Exosome isolationforproteomicanalysesandRNA profiling.
  25. (2011). Exosome secretion: molecular mechanisms androlesinimmuneresponses.Traffic 12,
  26. (2008). Exosome-like vesicles with dipeptidyl peptidase IV in human saliva.
  27. (2000). Exosome: from internal vesicle of the multivesicular body to intercellular signaling device.
  28. (2005). Exosomes and the MICA-NKG2D system in cancer.
  29. (2011). Exosomes as intercellular signalosomes and pharmacological effectors.
  30. (2010). Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumorresponseinvitro:anovelvaccine for renal cell carcinoma.
  31. (2002). Exosomes: composition, biogenesis and function.
  32. (2010). Exosomes: fit to deliver small RNA.
  33. (2011). Exosomes: immune properties and potential clinical implementations.
  34. (2011). Exosomes: secreted vesicles and intercellular communications.
  35. (2008). Glioblastoma microvesicles transportRNAandproteinsthatpromote tumour growth and provide diagnostic biomarkers.
  36. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.
  37. (1995). Hsp-70 is closely associated with the transferrin receptor in exosomes from maturing reticulocytes.
  38. (2008). Human tumor nanoparticles induce apoptosis of pancreatic cancer cells.
  39. (2010). Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes.
  40. (2004). Identification and proteomic profiling of exosomes in human urine.
  41. (2009). Identification of extracellular delta-catenin accumulation for prostate cancer detection.
  42. Identification of novel genes coding for small expressed RNAs.
  43. (2006). Immune protection effect of exosomes against attack of L1210 tumor cells.
  44. (2012). Immune-related microRNAs are abundant in breast milk exosomes.Int.J.Biol.Sci.8,118–123.
  45. (2008). Increasedexosomeproductionfrom tumour cell cultures using the Integra CELLine Culture System.
  46. (2011). Intracellular and extracellularmicroRNAsinbreastcancer.Clin.
  47. (2011). Introduction of theCIITAgeneintotumorcellsproducesexosomeswithenhancedantitumor effects.
  48. (2010). Isolation and purification of exosomes in urine.
  49. (2009). Large-scale proteomics and phosphoproteomics of urinary exosomes.
  50. (2010). Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line.
  51. (2003). Lipid raft-associated protein sorting in exosomes.
  52. (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior.
  53. (2005). MicroRNA gene expression deregulation in humanbreastcancer.CancerRes.65,
  54. (2008). MicroRNA signatures of tumor-derivedexosomesasdiagnostic biomarkers of ovarian cancer.
  55. (2008). MicroRNA-21 (miR21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
  56. (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
  57. (2011). Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.
  58. (2007). Plasma proteomics of pancreatic cancer patients by multidimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): upregulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer.
  59. (2005). Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol.
  60. (2004). Proteomic analysis of exosomes secreted by human mesothelioma cells.
  61. (2009). Proteomic and immunologic analyses of brain tumor exosomes.
  62. (2011). Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC.
  63. (2008). Proteomic profiling of exosomes: current perspectives.
  64. (2010). Proteomics analysis of bladder cancer exosomes.
  65. (2009). Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics 9,
  66. (2008). RAS: target for cancer therapy.
  67. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.
  68. (1989). Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions.
  69. (2006). Role of exosomes in immune regulation.
  70. (2007). Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev.
  71. (2010). Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation.
  72. (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells.
  73. (2011). Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Received:13October2011;paperpending published: 09
  74. (2006). Systemic inductionof theangiogenesisswitch by the tetraspanin D6.1A/CO-029. Cancer Res.
  75. (2010). The application of exosomesasananoscalecancervaccine.
  76. (1997). The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
  77. (2012). The genomic and proteomic content of cancer cell-derived exosomes.
  78. (1992). The Jeanne Manery-Fisher Memorial Lecture
  79. (2006). The regulation of exosome secretion:anovelfunctionofthep53 protein.
  80. (2009). The role of cbl family of ubiquitin ligases in gastric cancer exosomeinduced apoptosis of Jurkat T cells.
  81. (2011). The roles of tumor-derived exosomes in cancer pathogenesis.
  82. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits noncommercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
  83. (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
  84. (1987). Vesicle formation during reticulocytematuration.Association of plasma membrane activities with released vesicles (exosomes).

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.